Efficacy and Predictive Factors of Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy

Table 3

Comparison of clinical characteristics between the responder group and the nonresponder group with chronic CSC treated with spironolactone.

	Responder group, 24 eyes	Nonresponder group, 18 eyes	value
Demographics
Age (y)	45.67 ± 5.37	46.57 ± 8.23	0.71^a
Male (n)	16	13	>0.99^b
Hypertension (n)	8	7	>0.99^b
Disease duration (months)	7.22 ± 3.23	7.07 ± 2.73	0.89^a
Baseline BCVA (logMAR)	0.17 ± 0.28	0.27 ± 0.27	0.13^c
Clinical characteristics
PED (n)	11	8	>0.99^b
Double layer sign (n)	7	9	0.28^b
Ellipsoid integrity	19	3	0.001^b
ELM integrity	16	12	>0.99^b
Hyperreflective foci in the OS and ON layers	17	15	0.43^b
Subretinal deposits	8	10	0.28^b
Baseline SFCT	497.50 ± 99.36	365.50 ± 119.04	0.002^a
Baseline CCD (%)	6.71 ± 4.23	6.33 ± 3.83	0.80^a
Baseline Sattler + Haller density (%)	6.21 ± 3.56	5.36 ± 2.47	0.64^c
Abnormal choroidal vessels of choriocapillaris in OCTA	9	8	>0.99^b

CSC, central serous chorioretinopathy; BCVA, best-corrected visual acuity; PED, pigment epithelial detachment; ELM, external limiting membrane; OS, outer segment; ON layer, outer nuclear layer; DD, disc diameter; SFCT, subfoveal choroidal thickness; CCD, choriocapillaris density; OCTA, optical coherence tomography angiography. ^aIndependent sample Student’s t-test. ^bFisher’s exact test. ^cWilcoxon signed-rank sum test.